Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Jiaqi Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4431-9657; OpenAlex author ID A5101525107. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Pancreatic cancer-derived extracellular vesicles enhance chemoresistance by delivering KRAS G12D protein to cancer-associated fibroblasts. First author DOI 10.1016/j.ymthe.2025.01.023↗
  2. Inhibition of DEF-p65 Interactions as a Potential Avenue to Suppress Tumor Growth in Pancreatic Cancer. First author DOI 10.1002/advs.202401845↗
  3. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy. Co-author DOI 10.1016/j.ebiom.2022.103958↗
  4. Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy. Co-author DOI 10.1186/s13046-022-02273-w↗
  5. Genome-wide profiling of circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Co-author DOI 10.1002/1878-0261.12757↗
  6. Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patients with pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.009↗
  7. Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Co-author DOI 10.1186/s12943-017-0689-5↗
  8. Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. Co-author DOI 10.1038/srep13664↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 8 shared papers, 2015–2025 · strength 1.03
  2. Xueli Bai · 7 shared papers, 2017–2025 · strength 0.99
  3. Yifan Hong · 2 shared papers, 2024–2025 · strength 0.45
  4. Qi Zhang · 3 shared papers, 2015–2022 · strength 0.28
  5. Xinyuan Liu · 1 shared paper, 2025 · strength 0.26
  6. Sicong Huang · 1 shared paper, 2024 · strength 0.20
  7. Xiang Li · 2 shared papers, 2019–2020 · strength 0.17
  8. Tao Ma · 2 shared papers, 2019–2020 · strength 0.17
  9. Risheng Que · 2 shared papers, 2019–2020 · strength 0.17
  10. Lingyue Liu · 1 shared paper, 2022 · strength 0.16
  11. Xing Huang · 1 shared paper, 2022 · strength 0.16
  12. Jinyuan Song · 1 shared paper, 2022 · strength 0.16
  13. Tao Wei · 2 shared papers, 2017–2020 · strength 0.16
  14. Zhengtao Hong · 1 shared paper, 2022 · strength 0.14
  15. Tao Wei · 2 shared papers, 2015–2019 · strength 0.12
  16. Xiao Zhi · 1 shared paper, 2020 · strength 0.09
  17. Jian Zhang · 1 shared paper, 2020 · strength 0.09
  18. Qi Chen · 1 shared paper, 2020 · strength 0.09
  19. Wei Chen · 1 shared paper, 2020 · strength 0.09
  20. Jin Li · 1 shared paper, 2020 · strength 0.09
  21. Qi Chen · 1 shared paper, 2019 · strength 0.08
  22. Jianying Lou · 1 shared paper, 2019 · strength 0.08
  23. Lei Zheng · 1 shared paper, 2019 · strength 0.08
  24. Qi Chen · 1 shared paper, 2017 · strength 0.07
  25. Qi Zhang · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.